Stay updated on Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.

Latest updates to the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page
- Check4 days agoChange DetectedUpdated from v3.0.1 to v3.0.2, indicating a new patch release; the Back to Top link was removed as a minor UI change. No other substantive changes to core content were detected.SummaryDifference0.1%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%
- Check18 days agoChange DetectedThe web page has updated its facility name and location details, specifically highlighting Washington D.C. and the addition of various medical terms related to proteins and antibodies, while removing some previous location and cancer-related topics.SummaryDifference2%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.0%
- Check39 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11, indicating a revision in the content.SummaryDifference0.0%
- Check46 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.7%
Stay in the know with updates to Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.